Abstract Treatment for congenital adrenal hyperplasia (CAH) was introduced in the 1950s
following the discovery of the structure and function of adrenocortical hormones. Although …

Simple Summary The concept of locoregional lymphadenectomy (LND) in adrenocortical
cancer (ACC) has gained interest in recent years, but its definite prognostic and therapeutic …

International guidelines emphasise the role of local therapies (LT) for the treatment of
advanced adrenocortical carcinoma (ACC). However, large studies are lacking in this field …

Simple Summary Adrenocortical carcinoma (ACC) is a rare and malignant disease with a
poor prognosis in advanced disease. The complexity of ACC management requires a …

Context Adrenocortical carcinoma (ACC) is a rare endocrine malignancy that affects patients
across the age spectrum. Although the overall survival in patients with ACC is poor, there is …

Simple Summary Adrenocortical cancer (ACC) is a rare malignancy, often diagnosed late
and with a poor prognosis. Currently, ACC best management is achieved in referral centers …

Determination of body composition (the relative distribution of fat, muscle, and bone) has
been used effectively to assess the risk of progression and overall clinical outcomes in …

Adjuvant and neoadjuvant chemotherapy in the treatment of adrenocortical carcinoma
(ACC) is limited by few existing trials, most of which are retrospective. The drug mitotane has …

Abstract Importance Mitotane (Lysodren, o, p'-DDD [1-(o-chlorophenyl)-1-(p-chlorophenyl)-
2, 2-dichloroethane)] is currently the only United States Food and Drug Administration and …

Abstract Background Image-guided therapies (IGTs) are commonly used in oncology, but
their role in adrenocortical carcinoma (ACC) is not well defined. Materials and Methods A …